Polish medical lab operator Diagnostyka's annual profit jumps on higher test volumes
Published by Global Banking and Finance Review
Posted on April 24, 2025

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking and Finance Review
Posted on April 24, 2025

GDANSK (Reuters) -Polish medical laboratory operator Diagnostyka reported on Thursday an 80.9% year-on-year jump in its full-year net profit, mainly due to higher test volumes and a rise in average test prices.
The result was in line with a preliminary estimate of 223.3 million zlotys ($59.46 million).
WHY IT'S IMPORTANT
The results mark Diagnostyka's first earnings report since its February debut on the Warsaw Stock Exchange, with an offering valued at 1.70 billion zlotys in the exchange's first IPO of 2025.
CONTEXT
Diagnostyka controlled 22% of Poland's laboratory testing market in 2023, ahead of competitors Grupa Alab with 9% and Synevo, owned by Sweden's Medicover , with 4%, according to company data.
In April the medical laboratory operator acquired a 51% stake in Eurodiagnostic, which manages mobile diagnostic imaging laboratories, for about 23 million zlotys.
BY THE NUMBERS
Full-year operating revenue rose 23.6% year-on-year to 1.97 billion zlotys, driven by organic growth propelled by a 14.8% increase in test volumes and a 7.3% rise in average test prices, the company said.
On Tuesday, Diagnostyka's management recommended a dividend of 3.13 zlotys per share for 2024.
($1 = 3.7552 zlotys)
(Reporting by Julia Kotowska and Rafal W. Nowak; Editing by Susan Fenton)